

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 16 (2006) 1172-1174

## Asymmetric synthesis of the L-*fuco*-nojirimycin, a nanomolar $\alpha$ -L-fucosidase inhibitor

Mathieu Dubernet, Albert Defoin\* and Céline Tarnus

Laboratoire de Chimie Organique et Bioorganique, UMR 7015, Ecole Nationale Supérieure de Chimie de Mulhouse, Université de Haute-Alsace, 3, rue Alfred Werner, F-68093 Mulhouse Cédex, France

> Received 2 November 2005; revised 23 November 2005; accepted 24 November 2005 Available online 20 December 2005

Abstract—We describe the asymmetric synthesis of the 5-amino-5-deoxy-L-fucose (L-*fuco*-nojirimycin) which appears as a very potent fucosidase inhibitor with a  $K_i$  value of 1 nM. © 2005 Elsevier Ltd. All rights reserved.

The L-fucose is a more lipophilic sugar and has unusual properties. It is implicated in polysaccharide motives, as Sialyl Lewis X, which are important for inflammation processes and tumour migration.<sup>1–3</sup> The design of fucose mimics or the synthesis of nonhydrolysable analogues may be of biological importance.

Potent fucosidase inhibitors have already been described in L-fucose and L-lyxose series (Scheme 1). 1-Deoxy- or homo-L-*fuco*-nojirimycin derivatives L-1a, L-1c are nanomolar inhibitors of  $\alpha$ -L-fucosidase from various sources.<sup>4–8</sup> Amino-L-lyxose sugar  $2b^{9,10}$  and its 1-deoxy-derivative  $2a^{9-11}$  are likewise potent inhibitors of the  $\alpha$ -L-fucosidase of bovine kidney; the  $\alpha$ -homo derivative 2c has also a  $K_i$  value in the nanomolar range.<sup>12</sup>

We describe the asymmetric synthesis and the enzymatic evaluation of the L-*fuco*-nojirimycin L-**1b**, which is a new analogue of nojirimycin and which looks like a promising fucosidase inhibitor. We had already described the synthesis of its D-enantiomer D-**1b** via an asymmetric hetero-Diels–Alder reaction between sorbaldehyde dimethylacetal (**3**) and the chloro-nitroso dienophile **4** in the D-mannose series<sup>13,14</sup> (Scheme 2). This chiral dienophile had been developed by Kresze and Vasella.<sup>15</sup> Using the same methodology and the previously reported concurrent chloro-nitroso dienophiles **6a,b** in the 5-*O*-trityl-<sup>16</sup> and the 5-*O*-acetyl-D-ribose<sup>17</sup>



 $\mathbf{c} \mathbf{R} = \alpha - \mathbf{CH}_2 \mathbf{CH}_2 \mathbf{OH}$ 



Scheme 1.



Scheme 2.

series, respectively, the enantiomeric adduct has been prepared. An interesting comparison of these parent dienophiles is now possible.

Diels–Alder reaction of hexadienal dimethylacetal  $(3)^{18}$  with chloro-nitroso dienophiles **6a,b** was carried out as

Keywords: fuco-Nojirimycin; Fucosidase inhibitors; Asymmetric synthesis.

<sup>\*</sup> Corresponding author. Tel.: +33 03 89 33 68 64; fax +33 03 89 33 68 75; e-mail: A.Defoin@uha.fr

<sup>0960-894</sup>X/\$ - see front matter @ 2005 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2005.11.100



Scheme 3. Reagents and conditions: (a)  $HC(OMe)_3$ , MeOH,  $-10 \,^{\circ}C$ , 16-24 h; (b) aq  $Na_2CO_3$ ,  $CICO_2Bn$ ,  $0 \,^{\circ}C$ , 16 h; (c) cat.  $OsO_4$ , *N*-methyl-morpholine *N*-oxide, acetone/H<sub>2</sub>O, 40  $^{\circ}C$ , 16 h, yield 10% or 17% from 3; (d) 1—SOCl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, NEt<sub>3</sub>, 2—RuCl<sub>3</sub>, NaIO<sub>4</sub>, yield 90%; (e) 1—AcONH<sub>4</sub>, DMF, 70  $^{\circ}C$ ; 2—cat. H<sub>2</sub>SO<sub>4</sub>, dioxane; (f) 1—Tf<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, pyridine; 2—NaNO<sub>2</sub>, DMF, 30  $^{\circ}C$ ; 3—Na<sub>2</sub>CO<sub>3</sub>, MeOH, yield 65% from L-**8b**; (g) 1—H<sub>2</sub>-Pd/C, EtOH, 50  $^{\circ}C$ ; 2—SO<sub>2</sub>, H<sub>2</sub>O, 6 days, 40  $^{\circ}C$ , yield 60%.

**Table 1.** Comparison of data ( $[\alpha]_D$ , overall yield, enantiomeric excess (ee) value) for the obtained chiral diol L-8a with those of the known enantiomer D-8a<sup>13</sup> depending on the used dienophiles 4, 6a,b

Starting nitroso derivative	<b>4</b> <sup>13</sup>	6a	6b
Obtained chiral diol	D-8a	L- <b>8a</b>	L-8a
$\left[\alpha\right]_{\mathrm{D}}^{25}$ value (c 1, CHCl <sub>3</sub> )	-33	+28	+30
Yield of diol 8a from 3	35%	10%	17%
ee % value	>99	96	95

previously described with the mannose-derived dienophile  $4^{13}$  (Schemes 2 and 3): diene 3 (1–1.5 equiv) was reacted with dienophiles 6a,b (1 equiv) in a mixture of MeOH/methyl orthoformate at - 10 °C for 24 h. Compounds 6a,b were prepared just before use by oxidation of the corresponding oximes 5a,b with t-butyl hypochlorite. The adduct was recovered as hydrochloride L-7a in the aqueous phase after dilution with ether and extraction with an aqueous NaCl solution. Addition of excess  $Na_2CO_3$  to this aqueous solution of L-7a and acylation with benzyl chloroformate (1 equiv) under good stirring for 5 h furnished, after extraction with CH<sub>2</sub>Cl<sub>2</sub>, the crude N-protected adduct L-7b (crude yield ca. 50%). Subsequent bis hydroxylation as previously reported in D-series<sup>13</sup> gave the stable diol L-8a after chromatographic purification (AcOEt/cyclohexane, 1/1) in 10% or 17% yield according to the used nitroso dienophile (Table 1).

Table 1 compiles some data for the diol L-8a in comparison with those obtained for its enantiomer D-8a already prepared from the nitroso-D-mannose-derivative 4.<sup>13</sup> Lower overall yield was observed when the trityl derivative 6a was used as a dienophile. This is probably due to the difficulty in purifying the amorphous initial oxime 5a, compared to the nicely crystallised acetylated



one **5b**.<sup>17</sup> Determined enantiomeric excess (ee)<sup>19</sup> of L-**8a** was good (ca. 95%) and independent of the 5-substitution of the dienophile. This ee was similar to the one observed when hexadienoic acid was reacted with the dienophile **6b**.<sup>17</sup> Regarding the overall yields and the ee values which are given in Table 1, the mannose derivative

4 gave the best results among these dienophiles.

The inversion of the two hydroxyl groups in positions 4 and 5 of diol L-**8a** was carried out as for the D-enantiomer<sup>14</sup> (Scheme 3). The cyclic sulphate L-**8b** was obtained in 90% yield by reaction with SOCl<sub>2</sub> and oxidation of the resulting cyclic sulfite isomers with perruthenate ion. Opening of the sulphate L-**8b** with acetate anion following by acidolysis furnished two isomeric acetate alcohols L-**9** and L-**10** which were not separated. Their hydroxyl group was inverted by action of nitrite anion on the triflate and a subsequent methanolysis of the acetate group afforded the inverted diol L-**11** in 65% yield from sulphate L-**8b** (60% from diol L-**8a**).

Hydrogenolysis over Pd/C of the N-CO<sub>2</sub>Bn group and of the N–O bond of the diol L-11 followed by hydrolysis of the acetal group with SO<sub>2</sub> in water at 40 °C gave the crystalline L-*fuco*-nojirimycin sulfite adduct L-12, which was isolated after dilution with EtOH in 60% yield from diol L-11.

Hydrolysis of this sulfite adduct L-12 with baryte gave the L-*fuco*-nojirimycin L-1b in aqueous solution as a mixture of the imine form and of both the  $\alpha$ - and  $\beta$ -anomers in 11%, 46% and 43% proportion, respectively, at 295 K as in D-series<sup>14</sup> (Scheme 4). Hydrogenolysis over Pd/C of this mixture led to the known deoxy-derivative L-1a.<sup>4-7,20-22</sup>

Analytical data<sup>23</sup> of compounds L-1b, L-8a, L-8b, L-11 and L-12 were in agreement with those of the corresponding D-enantiomers<sup>13,14</sup> as well as data of the L-1a with those of the literature.<sup>4,20–22</sup>

**Table 2.** Inhibition of  $\alpha$ -L-fucosidase from bovine kidney ( $K_i$  in  $\mu$ M)<sup>24</sup> with compounds L-1a, L-1b and L-12 as well as with their D-enantiomers<sup>14</sup> D-1a, D-1b and D-12

Compound	1a	1b	12
L-Series	0.003 <sup>a</sup>	0.001	0.001
D-Series	660	3	13

<sup>a</sup>  $IC_{50} = 5 nM.$ 

Inhibition properties of the *L*-fuco-nojirimycin *L*-1b, its deoxy-derivative L-1a and its sulfite adduct L-12 were determined against  $\alpha$ -L-fucosidase activity<sup>24</sup> as well as those of their corresponding D-enantiomers<sup>14</sup> (Table 2).

All these compounds proved to be competitive inhibitors. L-fuco-Nojirimycin L-1b and its sulfite adduct L-12 appear to be very potent  $\alpha$ -L-fucosidase inhibitors with a  $K_i$  value of 1 nM. The deoxy-derivative L-1a is a less potent inhibitor and its potency is in agreement with the literature data against  $\alpha$ -L-fucosidase of bovine epididymis.<sup>4–7</sup> Their D-enantiomers are comparatively poor inhibitors, particularly the 1-deoxy-derivative D-1a.

We have described the asymmetric synthesis of the most potent nanomolar  $\alpha$ -L-fucosidase inhibitor, the L-fuconojirimycin (L-1b, L-fucose analogue of nojirimycin), in a 7% overall yield from hexadienal acetal (3) or in a 36%yield from the chiral diol L-8a. The increase of the inhibition potency for the amino-sugars L-1b, D-1b compared to their deoxy-derivatives L-1a, D-1a points out the importance of the anomeric hydroxyl group in the enzyme recognition as reported for other amino-sugars.<sup>25</sup>

## Acknowledgments

The support of the Centre National de la Recherche Scientifique (UMR 7015) is gratefully acknowledged. We thank Prof Jacques Streith for his interest in this work, Mme Christiane Strehler for the determination of the enantiomeric excess, Mr. Emmanuel Salomon and Dr. Isabelle Dosbaâ for the determination of the inhibition data and the student Delphine Thomas for her participation in this work.

## **References and notes**

- 1. Giannis, A. Angew. Chem., Int. Ed. Engl. 1994, 33, 178.
- 2. Sears, P.; Wong, Ch.-H. J. Chem. Soc., Chem. Commun. **1998**, 1161.
- 3. Fukuda, M. Bioorg. Med. Chem. 1995, 3, 207.
- 4. Fleet, G. W. J.; Shaw, A. N.; Evans, St. V.; Fellows, L. E. J. Chem. Soc., Chem. Commun. 1985, 841.
- 5. Winchester, B.; Barker, Ch.; Baines, S.; Jacob, G. S.; Namgoong, S. K.; Fleet, G. Biochem. J. 1990, 265, 277.
- 6. Paulsen, H.; Matzke, M.; Orthen, B.; Nuck, R.; Reutter, W. Liebigs Ann. Chem. 1990, 953.
- 7. Takayama, S.; Martin, R.; Wu, J.; Laslo, K.; Siusdak, G.; Wong, C.-H. J. Am. Chem. Soc. 1997, 119, 8146.
- 8. Fleet, G. W. J.; Namgoong, S. K.; Barker, Ch.; Baines, S.; Jacob, G.S.; Winchester, B. Tetrahedron Lett. 1989, 30, 4439.
- 9. Joubert, M.; Defoin, A.; Tarnus, C.; Streith, J. Synlett 2000, 1366.
- 10. Wong, Ch.-H.; Provencher, L.; Porco, J. A., Jr.; Jung, S.-H.; Wang, Y.-F.; Chen, L.; Wang, R.; Steensma, D. H. J. Org. Chem. 1995, 60, 1492.
- 11. Bierer, Lars, Ph.D Thesis, Stuttgart University, Germany, 1999 ( $K_i = 0.7 \ \mu M$  for **2a** against L-fucosidase of bovine epididymis).;
- 12. Chevrier, C.; Le Nouën, D.; Neuburger, M.; Defoin, A.; Tarnus, C. Tetrahedron Lett. 2004, 45, 5363.
- 13. Defoin, A.; Sarazin, H.; Streith, J. Tetrahedron 1997, 53, 13769.

- 14. Defoin, A.; Sarazin, H.; Streith, J. Tetrahedron 1997, 53, 13783.
- 15. Felber, H.; Kresze, G.; Prewo, R.; Vasella, A. Helv. Chim. Acta 1986, 69, 1137; corrigendum: Braun, H.; Charles, R.; Kresze, G.; Sabuni, M.; Winkler, J. Liebigs Ann. Chem. 1987, 1129.
- 16. Braun, H.; Felber, H.; Kresze, G.; Schmidtchen, Fr. P.; Prewo, R.; Vasella, A. Liebigs Ann. Chem. 1993, 261.
- 17. Defoin, A.; Joubert, M.; Heuchel, J.-M.; Streith, J. Synthesis 2000, 1719.
- Defoin, A.; Fritz, H.; Geffroy, G.; Streith, J. Helv. Chim. 18. Acta 1988, 71, 1642.
- 19. Determination conditions of the enantiomeric excess: column Chiralpak AD Daicel, eluent: 2-propanol/heptane 20/80, flow rate: 1 ml/min, 25 °C,  $\lambda$  = 260 nm. Analytical parameters: retention time for L(+)-8a Rt<sub>1</sub> = 9.4 min, for  $Rt_2 = 11.2 \text{ min};$  $k_1' = 2.26,$ D(-)-8a $k_2' = 2.81,$  $k'_2/k'_1 = 1.24$ , Resolution = 1.33.
- 20. Takahashi, Sh.; Kuzuhara, H. J. Chem. Soc., Perkin Trans. 1 1997, 607.
- 21. Paulsen, H.; Matzke, M. Liebigs Ann. Chem. 1988, 1121.
- 22. Polt, R.; Sames, D.; Chruma, J. J. Org. Chem. 1999, 64, 6147.
- 23. L-1a. Same <sup>1</sup>H NMR data as  $in^{20,21}$  and for D-1a<sup>14</sup>;  $[\alpha]_D^{20} = -52 \ (c \ 1, \ H_2O) \ \{\text{lit.}^4 \ [\alpha]_D^{20} = -48.8 \ (c \ 0.64, \ H_2O); \ \text{lit.}^{20} \ [\alpha]_D^{20} = -48 \ (c \ 0.2, \ H_2O); \ \text{lit.}^{21} \ [\alpha]_D^{20} = -46.9 \ (c \ 0.61, \ H_2O); \ \text{lit.}^{22} \ [\alpha]_D = -50 \ (c \ 1, \ D_2O); \ \text{lit.}^{14} + 49 \ (c \ 1, \ H_2O) \ \text{for}$ D-1a}.

L-1b. Same <sup>1</sup>H NMR data of the imine form,  $\alpha$ - and  $\beta$ -

anomers as for D-1a.<sup>14</sup> L-8a.  $[\alpha]_D^{25} = +30$  (c 1, CHCl<sub>3</sub>) {lit.<sup>13</sup>  $[\alpha]_D^{20} = -33$  (c 1, CHCl<sub>3</sub>) for the D-enantiomer}. Same IR and <sup>1</sup>H NMR data as for D-8a;<sup>13</sup> <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz, 295 K): 156.4 (CO); 136.1 (Car-s); 128.6 (2 Car-m, Car-p); 128.2 (2 Car-o); 104.3 (CH(OMe)<sub>2</sub>); 75.8 (C(6)); 68.8 (C(4)); 67.9 (*CH*<sub>2</sub>Ph); 64.8 (C(5)); 56.4 (OMe); 55.4 (C(3); 53.3 (OMe); 14.4 (Me-3). HR-MS (Q-Tof), calcd for  $C_{16}H_{23}NO_7$ : 341.1475; found: 341.1431. Anal. calcd for C<sub>16</sub>H<sub>23</sub>NO<sub>7</sub> (341.36): C, 56.29; H, 6.79; N, 4.10. Found: C, 56.1; H, 7.1; N, 4.1.

**L-8b.**  $[\alpha]_D^{20} = +63$  (c 1, CHCl<sub>3</sub>) {lit.<sup>14</sup>  $[\alpha]_D^{20} = -68$  (c 2, CHCl<sub>3</sub>) for **D-8b**}. Same IR and <sup>1</sup>H NMR data as for **D**-8b;<sup>14</sup><sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz, 295 K): 154.5 (CO); 135.2 (Car-s); 128.7 (2 Car-m); 128.6 (Car-p); 128.3 (2 Car-o); 101.8 (CH(OMe)<sub>2</sub>); 79.7 (C(4)); 76.9 (C(6)); 74.7 (C(5)); 68.6 ( $CH_2$ Ph); 55.8, 55.3 (OMe, C(3)); 51.1(OMe); 14.2 (Me-3). HR-MS (Q-Tof), calcd for C16H21NO9S: 403.0937; found: 403.0909. Anal. calcd for C<sub>16</sub>H<sub>21</sub>NO<sub>9</sub>S (403.41): C, 47.64; H, 5.25; N, 3.47. Found: C, 47.6; H, 5.5; N, 3.4.

L-11.  $[\alpha]_D^{20} = +24$  (c 1, CHCl<sub>3</sub>) {lit.<sup>14</sup>  $[\alpha]_D^{20} = -19$  (c 1, CHCl<sub>3</sub>) for D-11}. Same IR and <sup>1</sup>H NMR data as for D-11<sup>14</sup>, <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz, 295 K): 154.9 (CO); 125.9 (COR) 128.5 (COR) 128.5 (COR) 135.8 (Car-s); 128.5 (2 Car-m); 128.3 (Car-p); 128.1 (2 Car-o); 101.9 (CH(OMe)<sub>2</sub>); 81.3 (C(6)); 67.9, 67.5, 67.3 (CH<sub>2</sub>Ph, C(4), C(5)); 55.8 (OMe); 54.1, 53.3 (C(3), OMe); 12.0 (Me-3). HR-MS (Q-Tof), calcd for C<sub>16</sub>H<sub>23</sub>NO<sub>7</sub>: 341.1475; found: 341.1436.

L-12. Mp = 242–250 °C (dec.), (lit.<sup>14</sup> 240–250 °C, dec. for D-12).  $[\alpha]_D^{20} = -8.2 (c \ 1, \ H_2O) \{ \text{lit.}^{14} \ [\alpha]_D^{20} = +9 (c \ 1, \ H_2O)$ for D-12}. Same IR, <sup>1</sup>H NMR and <sup>13</sup>C NMR data as for D-12.<sup>14</sup> Anal. calcd for  $C_6H_{13}NO_6S$  (227.23): C, 31.71; H, 5.77; N, 6.16; S, 14.11. Found: C, 31.8; H, 5.8; N, 6.0; S, 14.2.

- 24. Inhibition determination conditions: acetate buffer, pH 5.5,  $K_{\rm m} = 0.15$  mM, 30 °C; all measured compounds were stable under these conditions.
- 25. Behr, J.-B.; Chevrier, C.; Defoin, A.; Tarnus, C.; Streith, J. Tetrahedron 2003, 59, 543.